Alexander Kocherscheidt
Analyst · JPMorgan
Thank you very much, Stefan, and a warm welcome from me as well. Ladies and gentlemen, I will now walk you through our business and financial performance in the second quarter. Let's have a closer look at the group performance. As Stefan has already highlighted, we had an excellent second quarter throughout all key performance indicators. Order intake increased significantly by 15.4% organically with all divisions contributing to this positive development, except for PFA. From a customer industry perspective, once again and for several quarters in a row, dairy processing and dairy farming continued to be strong. In addition, food and other industries were showing good demand. Translational FX effects became smaller. While we had an adverse translational FX effect of more than 3% in the first quarter, it shrunk to 1% in the second quarter. Sales grew organically by 11.0% driven by excellent performance in both new machine and service sales. Organic growth in the new machine business reached 11.6%, supported by double-digit growth rates in almost all divisions. The service business continued its growth trajectory and reported an organic growth rate of 10.2%. This marks the 30 -- sorry, the 23rd quarter such a high number, it's difficult, 23rd quarter in a row with organic service sales growth, an impressive performance. On the back of the slightly stronger growth in the new machine business, the service sales share declined by 0.5 percentage points to 39.6%. The EBITDA before restructuring expenses rose by EUR 23 million to EUR 251 million, resulting in a corresponding year-over-year margin expansion of 0.9 percentage points to 17.4%. Significantly higher volume and better gross margin were the drivers of the profitability increase. Moving on to the divisional performance. I will start with Pure Flow Processing, which reported very strong top line growth. So order intake and sales, while the EBITDA margin declined slightly at a high level. Order intake grows organically by 9.8% year-over-year, driven by orders below EUR 5 million. Demand was strongest in food, dairy processing and marine, but also beverage, energy and distribution and storage contributed to the impressive growth rate. Thus, order intake strength was broad-based across different customer industries. Organic sales grew significantly by 12.9% year-over-year, driven by very strong growth rates in new machines and service business. As the new machine business grew even more than service sales this quarter, the service sales share decreased on a high level from 47.0% in the second quarter of 2025 to 46.2% in the second quarter of 2026. EBITDA before restructuring expenses rose by EUR 13 million year-over-year to EUR 145 million, driven by higher gross profit, which was partly offset by increased operating costs, such as higher selling expenses in line with our order intake development. The corresponding EBITDA margin declined on a high level by 0.5 percentage points year-over-year to 27.5% in the quarter. Turning to Nutrition Plant Engineering, which caught up strongly from a slow first quarter. The division reported impressive numbers across all key performance indicators, significant order intake growth, strong sales as well as a substantial EBITDA margin expansion. As a result of this performance, all key indicators turned from a negative performance in the first quarter to a positive one in the first half. Order intake for the second quarter was up organically by more than 40%, this was driven by a very strong performance of orders between EUR 1 million and EUR 15 million as well as two large orders from the dairy processing industry, which totaled EUR 34 million. The prior year quarter contained no large orders. In terms of customer industries, dairy processing remains strong. This is not only driven by the two large Asian dairy processing orders, even without these two large orders, this customer industry would have been a strong growth contributor. In addition, Pharma showed good demand in the quarter. Sales increased organically by 10.6% year-over-year. Service sales continued its growth trajectory, increasing organically by 11.5% year-over-year. At the same time, new machine sales rebounded as expected and promised after reporting a decline in the first quarter. As mentioned already in our first quarter call, we expected an improvement in new machine sales kicking in, in the second quarter. EBITDA before restructuring expenses increased from EUR 45 million in the prior year quarter to EUR 56 million in the second quarter of 2026 on the back of higher sales volume and better gross margin. The corresponding EBITDA margin rose strongly by 1.3 percentage points year-over-year to 11.3%. Continuing with Pharma & Food Applications, which delivered strong sales growth and a substantial profitability expansion. Order intake, however, declined organically by 9.6% due to timing of orders. Base orders, which are orders below EUR 1 million, were growing by more than 6% in the quarter, while medium-sized orders were down. Sales grew by 8.5% year-over-year in organic terms driven by both strong new machine and service sales. The new machine business delivered an organic growth rate of 9.2%, while service grew at 7.2%. As a result, the service sales share decreased from 34.5% in the prior year quarter to 33.3% in the quarter. The impressive track record of continuous profitability improvement which the division has built up over the last years continued in the second quarter. Absolute EBITDA before restructuring expenses and the corresponding margin reached new record levels for the quarter. EBITDA rose substantially by 30% year-over-year to EUR 45 million, driven by volume and significantly higher gross margin. For the first time ever, the respective margin crossed the 16% mark and reached 16.2%, an outstanding achievement. Finally, Farm Technologies. Farm Technologies reported another quarter of double-digit growth rates in order intake and sales. Let me give you some more details here. The favorable market environment for dairy farmers, which began in December 2024, continued steadily throughout 2025 and the first half of 2026, this translated once again into a notable increase in order intake. Order intake rose by 11.4% organically due to strong demand for both automated and conventional milking systems in the new machine business area. In terms of order sizes, base orders were the growth driver. Organic sales rose significantly by 15.4%. New machine sales continued their strong performance since middle of last year with a substantial year-over-year organic increase of 22.6%. Service sales grew organically at 8.6%, and as a result of the significant outperformance of the new machine business, the service sales share declined from a high level of 51.1% in the second quarter of 2025 and to 47.8% in the second quarter of 2026. On the back of higher sales volume, EBITDA before restructuring expenses rose by EUR 3 million year-over-year to EUR 30 million. The corresponding EBITDA margin declined slightly by 0.2 percentage points to 14.2% because of the lower service sales share and product mix effects. Let me close the divisional chapter with an overview of the EBITDA growth contribution in the first half and in the second quarter of 2026. There are two important messages. Firstly, we have been able to increase our EBITDA before restructuring expenses in both time periods considerably. Secondly, all divisions contributed to this positive development. This underlines our broad-based strength resulting from our price and cost discipline as well as savings from our procurement and production optimization efforts. Let me now turn to another important topic, net working capital. Year-over-year, net working capital declined by EUR 27 million to EUR 396 million. This reduction was driven by a combination of higher trade payables and higher contract liabilities. The high volume of large orders over the last 4 quarters led to higher advanced payments, which are reflected in the increase in contract liabilities. This resulted in a net working capital to sales ratio of 7.0%, placing us at the bottom of the guided corridor of 7% to 9%. On a rolling last 4 quarters basis, which smooths seasonality, the ratio was even lower at 6.3%. Free cash flow reached an outstanding level, marking the highest second quarter free cash flow in 6 years. Let's have a look at the main drivers. After a moderate net working capital outflow of EUR 12 million and a EUR 26 million outflow in the others position, which mainly results from miscellaneous balance sheet movements like VAT, operating cash flow stood at EUR 185 million in the second quarter. CapEx related cash outflow was relatively low at EUR 39 million compared with our full year 2026 guidance of around EUR 240 million. As in previous years, we expect CapEx to ramp up in the second half of 2026. As a result, free cash flow was very strong, amounting to EUR 151 million. After deducting lease payments and interest paid, net cash flow amounted to EUR 131 million. The strong net cash flow was offset by the dividend payment. But even so, we ended the quarter with a net cash position of EUR 71 million. In the first half, free cash flow was still negative at EUR 39 million. However, we saw a very strong catch up in the second quarter. We are, therefore, on track to achieve roughly the same level of free cash flow for the full year as in 2025. Free cash flow generation over the last 4 quarters has been strong, reaching EUR 483 million. The corresponding cash conversion ratio, which indicates how much of the EBITDA before restructuring expenses has been converted into free cash flow before restructuring expenses landed at a solid 54%. With that, I hand back to Stefan for the outlook.